These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 22872786)
1. Molecular serum markers of liver fibrosis. Liu T; Wang X; Karsdal MA; Leeming DJ; Genovese F Biomark Insights; 2012; 7():105-17. PubMed ID: 22872786 [TBL] [Abstract][Full Text] [Related]
2. Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers. Veidal SS; Bay-Jensen AC; Tougas G; Karsdal MA; Vainer B Dis Markers; 2010; 28(1):15-28. PubMed ID: 20164543 [TBL] [Abstract][Full Text] [Related]
3. Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. Schierwagen R; Leeming DJ; Klein S; Granzow M; Nielsen MJ; Sauerbruch T; Krag A; Karsdal MA; Trebicka J Front Physiol; 2013; 4():195. PubMed ID: 23908632 [TBL] [Abstract][Full Text] [Related]
4. An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution. Pehrsson M; Manon-Jensen T; Sun S; Villesen IF; Castañé H; Joven J; Patel K; Goodman Z; Nielsen MJ; Bay-Jensen AC; Leeming DJ; Mortensen JH; Karsdal MA Liver Int; 2022 Jul; 42(7):1605-1617. PubMed ID: 35384259 [TBL] [Abstract][Full Text] [Related]
5. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis--identification and validation of a novel biochemical marker assay. Veidal SS; Karsdal MA; Vassiliadis E; Nawrocki A; Larsen MR; Nguyen QH; Hägglund P; Luo Y; Zheng Q; Vainer B; Leeming DJ PLoS One; 2011; 6(9):e24753. PubMed ID: 21935455 [TBL] [Abstract][Full Text] [Related]
6. Advances in the clinical use of collagen as biomarker of liver fibrosis. Meurer SK; Karsdal MA; Weiskirchen R Expert Rev Mol Diagn; 2020 Sep; 20(9):947-969. PubMed ID: 32865433 [TBL] [Abstract][Full Text] [Related]
7. Hepatic fibrosis: are any of the serum markers useful? Oh S; Afdhal NH Curr Gastroenterol Rep; 2001 Feb; 3(1):12-8. PubMed ID: 11177689 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease. El-Gindy I; El Rahman AT; El-Alim MA; Zaki SS Egypt J Immunol; 2003; 10(1):27-35. PubMed ID: 15719620 [TBL] [Abstract][Full Text] [Related]
9. Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis--a serological evaluation. Leeming DJ; Byrjalsen I; Jiménez W; Christiansen C; Karsdal MA Liver Int; 2013 Mar; 33(3):439-47. PubMed ID: 23279004 [TBL] [Abstract][Full Text] [Related]
10. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease? Karsdal MA; Henriksen K; Leeming DJ; Woodworth T; Vassiliadis E; Bay-Jensen AC Clin Biochem; 2010 Jul; 43(10-11):793-804. PubMed ID: 20381482 [TBL] [Abstract][Full Text] [Related]
11. Characterization of serological neo-epitope biomarkers reflecting collagen remodeling in clinically stable chronic obstructive pulmonary disease. Sand JM; Martinez G; Midjord AK; Karsdal MA; Leeming DJ; Lange P Clin Biochem; 2016 Oct; 49(15):1144-1151. PubMed ID: 27614218 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Gressner OA; Weiskirchen R; Gressner AM Clin Chim Acta; 2007 Jun; 381(2):107-13. PubMed ID: 17399697 [TBL] [Abstract][Full Text] [Related]
13. Serum biomarkers for liver fibrosis. Chen Z; Ma Y; Cai J; Sun M; Zeng L; Wu F; Zhang Y; Hu M Clin Chim Acta; 2022 Dec; 537():16-25. PubMed ID: 36174721 [TBL] [Abstract][Full Text] [Related]
14. Hepatic fibrosis and its serum markers: a review. Gabrielli GB; Corrocher R Dig Dis; 1991; 9(5):303-16. PubMed ID: 1752069 [TBL] [Abstract][Full Text] [Related]
15. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Lieber CS; Weiss DG; Paronetto F; Alcohol Clin Exp Res; 2008 Jun; 32(6):1031-9. PubMed ID: 18422837 [TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Veidal SS; Vassiliadis E; Barascuk N; Zhang C; Segovia-Silvestre T; Klickstein L; Larsen MR; Qvist P; Christiansen C; Vainer B; Karsdal MA Liver Int; 2010 Oct; 30(9):1293-304. PubMed ID: 20666994 [TBL] [Abstract][Full Text] [Related]
18. Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy. Rubiś P; Wiśniowska-Śmialek S; Wypasek E; Biernacka-Fijalkowska B; Rudnicka-Sosin L; Dziewiecka E; Faltyn P; Khachatryan L; Karabinowska A; Kozanecki A; Tomkiewicz-Pająk L; Podolec P Inflamm Res; 2016 Dec; 65(12):941-949. PubMed ID: 27516211 [TBL] [Abstract][Full Text] [Related]
19. Serum laboratory markers for noninvasive diagnosis and monitoring of liver fibrogenesis in patients with chronic liver diseases. Vozar I Bratisl Lek Listy; 2005; 106(3):123-6. PubMed ID: 16026147 [TBL] [Abstract][Full Text] [Related]
20. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Cross T; Antoniades C; Harrison P Hepatol Res; 2008 Aug; 38(8):762-9. PubMed ID: 18462378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]